PLOS ONE (open access)
Objective
Early
recurrence (ER) after completion of therapeutic regimen in
advanced-stage ovarian cancer is a challenging clinical situation.
Patients are perceived as invariably having a poor prognosis. We
investigated the possibility of defining different prognostic subgroups
and the parameters implicated in prognosis of ER patients.
Conclusion
ER
(early recurrence)
in advanced-stage ovarian cancer
does not inevitably portend a
short-term poor prognosis. RD
(residual disease) status after initial cytoreduction
strongly modulates OS, that gives additional support to the concept of
maximum surgical effort even in patients who will experience early
recurrence. The heterogeneity in outcomes within the ER group suggests a
role for tumor biology in addition to classical clinical parameters.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.